About the Company
Arch Therapeutics, Inc. (Arch) is a biotechnology company developing an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis*) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, “stasis and barrier applications.”
Physicians, industry and patients could benefit greatly from a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in a variety of consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools designed to resolve these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
FRAMINGHAM, MA–(Marketwired – Feb 16, 2017) – Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. ( OTCQB : ARTH ), developer of innovative materials as hemostatic and wound care devices, provided a corporate update during a live webcast this...
FRAMINGHAM, MA–(Marketwired – Feb 8, 2017) – Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. ( OTCQB : ARTH ) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, will present at...
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
FRAMINGHAM, MA–(Marketwired – Feb 2, 2017) – Arch Therapeutics, Inc. ( OTCQB : ARTH ) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, announced that the U.S. Patent and Trademark Office...
Arch Therapeutics to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
WESTPORT, CT / ACCESSWIRE / January 13, 2017 / Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and...